2-methyl-N-{[4-(trifluoromethyl)phenyl]methyl}propanamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-methyl-N-{[4-(trifluoromethyl)phenyl]methyl}propanamide
• 英文别名: 2-methyl-N-[[4-(trifluoromethyl)phenyl]methyl]propanamide
• 化学式: C₁₂H₁₄F₃NO
• mdl: MFCD02666628
• 分子量: 245.24
• InChiKey: PZGUVWCSOIMHSW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• NOVEL NAPHTHYRIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS
  申请人：Merck Patent GmbH

  公开号：US20160016951A1

  公开（公告）日：2016-01-21

  The present invention relates to naphthyridine and isoquinoline compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of CDK8/19, and for the treatment of CDK8/19-related disorders.

  本发明涉及萘啶和异喹啉化合物，以及由此组成的药物可接受的组合物，作为CDK8/19的抑制剂，用于治疗与CDK8/19相关疾病。
• Compounds, Compositions and Methods Comprising Pyridazine Derivatives
  申请人：Russell Michael Geoffrey Neil

  公开号：US20100267706A1

  公开（公告）日：2010-10-21

  The present invention relates to compounds, compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1 or 2 or encompassed by formulas I, Ia, II, III, and IV) or compositions comprising these compounds, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

  本发明涉及化合物、组合物和方法，用于治疗动物中对抑制功能性囊性纤维化跨膜传导调节因子（CFTR）多肽敏感的疾病，通过向需要的哺乳动物中给予本文中定义的化合物的有效量（包括表1或2中列出的化合物或由公式I、Ia、II、III和IV包含的化合物）或包含这些化合物的组合物，从而治疗该疾病。本发明特别涉及一种治疗腹泻和多囊肾病的方法。
• [EN] COMPOUNDS FOR TREATING INFECTIONS CAUSED BY RIFAMPICIN-RESISTANT BACTERIA<br/>[FR] COMPOSÉS POUR LE TRAITEMENT D'INFECTIONS PROVOQUÉES PAR DES BACTÉRIES RÉSISTANTES À LA RIFAMPICINE
  申请人：DEMURIS LTD

  公开号：WO2020021252A1

  公开（公告）日：2020-01-30

  Novel compounds of formulae (l)-(lll) are provided, as well as pharmaceutical compositions comprising the novel compounds. Also described are therapeutic uses of the novel compounds, in particular in relation to the treatment of infections caused by rifampicin- resistant bacteria, e.g. rifampicin-resistant tuberculosis.

  提供了公式（l）-（lll）的新化合物，以及包含这些新化合物的药物组合物。还描述了新化合物的治疗用途，特别是与治疗由利福平耐药细菌引起的感染有关，例如利福平耐药结核病。
• Lysyl oxidase-like 2 inhibitors and uses thereof
  申请人：PharmAkea, Inc.

  公开号：US10766860B2

  公开（公告）日：2020-09-08

  Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

  本文描述了作为 LOXL2 抑制剂的化合物、制造此类化合物的方法、包含此类化合物的药物组合物和药物，以及使用此类化合物治疗与 LOXL2 活性相关的病症、疾病或失调的方法。
• INHIBITORS OF INTEGRIN ALPHA2BETA1 WITH MODIFIED UREA MOIETY
  申请人：DeGrado William F.

  公开号：US20090197861A1

  公开（公告）日：2009-08-06

  Novel compounds inhibiting the integrin α2β1/GPIa-IIa receptor are disclosed. Also disclosed are pharmaceutical compositions containing the compounds, as well as methods of their therapeutic use. The compounds disclosed are useful, inter alia, as inhibitors of integrin α2β1/GPIa-IIa-mediated activity.